Study of two drugs for advanced bile duct or gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old.
- You have advanced (stage IIIA or higher) bile duct or gallbladder cancer that cannot be removed with surgery and has progressed after at least one prior treatment.
- You have at least one measurable tumor (at least 1 cm in size) on a CT scan or an enlarged lymph node (at least 1.5 cm).
- You are in good enough health to carry out daily activities (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You have adequate organ function as shown by blood and urine tests.
- You have not had prior treatment with TROP2-targeted therapy or topoisomerase I inhibitors.
- You do not have active infections like hepatitis B or C, or unstable autoimmune diseases.
- You are willing to use effective contraception during the study and for 6 months after the last dose.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a special form of chemotherapy (paclitaxel micelle) and an immunotherapy for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that has not responded to or stopped working after first treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs for people with advanced bile duct or gallbladder cancer that has not been treated yet. It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a combination of four drugs for people with advanced bile duct or gallbladder cancer that has spread. The drugs target HER2, a protein on some cancer cells, and may help shrink tumors or slow their growth.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.